PMID- 28376896
OWN - NLM
STAT- MEDLINE
DCOM- 20171004
LR  - 20181113
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 16
IP  - 1
DP  - 2017 Apr 4
TI  - Regulation of visceral and epicardial adipose tissue for preventing 
      cardiovascular injuries associated to obesity and diabetes.
PG  - 44
LID - 10.1186/s12933-017-0528-4 [doi]
LID - 44
AB  - Nowadays, obesity is seriously increasing in most of the populations all over the 
      world, and is associated with the development and progression of high-mortality 
      diseases such as type-2 diabetes mellitus (T2DM) and its subsequent 
      cardiovascular pathologies. Recent data suggest that both body fat distribution 
      and adipocyte phenotype, can be more determinant for fatal outcomes in obese 
      patients than increased general adiposity. In particular, visceral adiposity is 
      significantly linked to long term alterations on different cardiac structures, 
      and in developed forms of myocardial diseases such as hypertensive and ischaemic 
      heart diseases, and diabetic cardiomyopathy. Interestingly, this depot may be 
      also related to epicardial fat accumulation through secretion of lipids, 
      adipokines, and pro-inflammatory and oxidative factors from adipocytes. Thus, 
      visceral adiposity and its white single-lipid-like adipocytes, are risk factors 
      for different forms of heart disease and heart failure, mainly in higher degree 
      obese subjects. However, under specific stimuli, some of these adipocytes can 
      transdifferentiate to brown multi-mitochondrial-like adipocytes with 
      anti-inflammatory and anti-apoptotic proprieties. Accordingly, in order to 
      improve potential cardiovascular abnormalities in obese and T2DM patients, 
      several therapeutic strategies have been addressed to modulate the visceral and 
      epicardial fat volume and phenotypes. In addition to lifestyle modifications, 
      specific genetic manipulations in adipose tissue and administration of PPARgamma 
      agonists or statins, have improved fat volume and phenotype, and cardiovascular 
      failures. Furthermore, incretin stimulation reduced visceral and epicardial fat 
      thickness whereas increased formation of brown adipocytes, alleviating insulin 
      resistance and associated cardiovascular pathologies.
FAU - Gonzalez, N
AU  - Gonzalez N
AD  - Renal, Vascular and Diabetes Laboratory, Instituto de Investigaciones 
      Sanitarias-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma, Madrid, Spain.
AD  - Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders 
      (CIBERDEM) Network, Madrid, Spain.
FAU - Moreno-Villegas, Z
AU  - Moreno-Villegas Z
AD  - Renal, Vascular and Diabetes Laboratory, Instituto de Investigaciones 
      Sanitarias-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma, Madrid, Spain.
FAU - Gonzalez-Bris, A
AU  - Gonzalez-Bris A
AD  - Renal, Vascular and Diabetes Laboratory, Instituto de Investigaciones 
      Sanitarias-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma, Madrid, Spain.
FAU - Egido, J
AU  - Egido J
AD  - Renal, Vascular and Diabetes Laboratory, Instituto de Investigaciones 
      Sanitarias-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma, Madrid, Spain.
AD  - Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders 
      (CIBERDEM) Network, Madrid, Spain.
FAU - Lorenzo, O
AU  - Lorenzo O
AUID- ORCID: 0000-0001-5515-6078
AD  - Renal, Vascular and Diabetes Laboratory, Instituto de Investigaciones 
      Sanitarias-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma, Madrid, Spain. 
      olorenzo@fjd.es.
AD  - Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders 
      (CIBERDEM) Network, Madrid, Spain. olorenzo@fjd.es.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170404
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Incretins)
SB  - IM
MH  - Adipose Tissue/drug effects/*metabolism
MH  - Adipose Tissue, Brown/drug effects/metabolism
MH  - Cardiovascular Diseases/epidemiology/*metabolism/prevention & control
MH  - Diabetes Mellitus, Type 2/epidemiology/*metabolism/prevention & control
MH  - Humans
MH  - Incretins/pharmacology/therapeutic use
MH  - Intra-Abdominal Fat/drug effects/*metabolism
MH  - Obesity/epidemiology/metabolism/prevention & control
MH  - Pericardium/drug effects/*metabolism
PMC - PMC5379721
OTO - NOTNLM
OT  - BAT
OT  - Epicardial adipose tissue
OT  - Incretin
OT  - PPARgamma
OT  - Statin
OT  - Visceral adipose tissue
OT  - WAT
EDAT- 2017/04/06 06:00
MHDA- 2017/10/05 06:00
PMCR- 2017/04/04
CRDT- 2017/04/06 06:00
PHST- 2017/02/10 00:00 [received]
PHST- 2017/03/28 00:00 [accepted]
PHST- 2017/04/06 06:00 [entrez]
PHST- 2017/04/06 06:00 [pubmed]
PHST- 2017/10/05 06:00 [medline]
PHST- 2017/04/04 00:00 [pmc-release]
AID - 10.1186/s12933-017-0528-4 [pii]
AID - 528 [pii]
AID - 10.1186/s12933-017-0528-4 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2017 Apr 4;16(1):44. doi: 10.1186/s12933-017-0528-4.